Prices for lab monkeys surge on China biotech boom
More drugs entering middle or late-stage development drive up demand
Related reading
Why investors are chasing US biotechs with Chinese characteristics
Drugs developed in Asian nation are increasingly being used to seed US start-ups
Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth
US regulator to curtail use of primate testing in drug trials
FDA decision aligns with Trump administration’s effort to lower pharma costs by eliminating lab monkey requirement
Big Pharma is falling out of love with Britain
Life sciences should be a natural place to look for growth
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
Global pharmaceutical companies are aggressively searching for new medicines in China
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands